File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating adipocyte fatty acid–binding protein is reduced by continuous positive airway pressure treatment for obstructive sleep apnea—a randomized controlled study

TitleCirculating adipocyte fatty acid–binding protein is reduced by continuous positive airway pressure treatment for obstructive sleep apnea—a randomized controlled study
Authors
KeywordsAdipocyte fatty acid–binding protein
Obstructive sleep apnea
Continuous positive airway pressure
Biomarkers
Issue Date2020
PublisherSpringer Verlag. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/11325
Citation
Sleep and Breathing, 2020, v. 24 n. 3, p. 817-824 How to Cite?
AbstractPurpose: The circulating level of adipocyte fatty acid–binding protein (AFABP), a biomarker with prognostic and therapeutic importance in metabolic disorders, has been shown to be elevated in obstructive sleep apnea (OSA). This randomized controlled study aimed to investigate the effect of continuous positive airway pressure (CPAP) treatment for OSA on AFABP levels. Methods: Consecutive subjects attending sleep study were invited if they were confirmed to have severe OSA and were free of metabolic diseases. Participants were randomized (1:1) into CPAP or observation group for 4 weeks. Demographics, anthropometric data, and circulating biomarkers were checked at baseline and after the 4-week study period. Results: Ninety subjects were randomized. The mean age was 46 ± 9 years old; 82% were male. Their mean body mass index (BMI) was 29 ± 5 kg/m2. By intention-to-treat approach, the CPAP group showed significant reductions in Epworth sleepiness scale and morning systolic blood pressure (− 7.2 mmHg, − 12.7 to − 1.7 mmHg, p = 0.011), but no significant difference in AFABP, adiponectin, C-reactive protein (CRP), and 8-isoprostane levels. In the per-protocol analysis, when only those who were compliant to CPAP were included, a significant reduction in AFABP (− 7.32 ng/ml, − 13.58, − 1.06, p = 0.023) were found in the CPAP-treated group compared with the control group, along with improvements in clinical parameters. Changes in AFABP were independently associated with both systolic blood pressure (β = 0.289, p = 0.028) and diastolic blood pressure (β = 0.217, p = 0.030). Conclusion: CPAP therapy used regularly over 4 weeks for severe OSA lowered circulating AFABP level, suggesting a potential beneficial effect of OSA treatment on alleviating metabolic risks. Trial registration: The research protocol was registered at the National Institutes of Health clinical trials registry (NCT01173432).
Persistent Identifierhttp://hdl.handle.net/10722/287359
ISSN
2023 Impact Factor: 2.1
2023 SCImago Journal Rankings: 0.753
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, MMS-
dc.contributor.authorMak, JCW-
dc.contributor.authorChong, PWC-
dc.contributor.authorLam, DCL-
dc.contributor.authorIp, MSM-
dc.date.accessioned2020-09-22T02:59:51Z-
dc.date.available2020-09-22T02:59:51Z-
dc.date.issued2020-
dc.identifier.citationSleep and Breathing, 2020, v. 24 n. 3, p. 817-824-
dc.identifier.issn1520-9512-
dc.identifier.urihttp://hdl.handle.net/10722/287359-
dc.description.abstractPurpose: The circulating level of adipocyte fatty acid–binding protein (AFABP), a biomarker with prognostic and therapeutic importance in metabolic disorders, has been shown to be elevated in obstructive sleep apnea (OSA). This randomized controlled study aimed to investigate the effect of continuous positive airway pressure (CPAP) treatment for OSA on AFABP levels. Methods: Consecutive subjects attending sleep study were invited if they were confirmed to have severe OSA and were free of metabolic diseases. Participants were randomized (1:1) into CPAP or observation group for 4 weeks. Demographics, anthropometric data, and circulating biomarkers were checked at baseline and after the 4-week study period. Results: Ninety subjects were randomized. The mean age was 46 ± 9 years old; 82% were male. Their mean body mass index (BMI) was 29 ± 5 kg/m2. By intention-to-treat approach, the CPAP group showed significant reductions in Epworth sleepiness scale and morning systolic blood pressure (− 7.2 mmHg, − 12.7 to − 1.7 mmHg, p = 0.011), but no significant difference in AFABP, adiponectin, C-reactive protein (CRP), and 8-isoprostane levels. In the per-protocol analysis, when only those who were compliant to CPAP were included, a significant reduction in AFABP (− 7.32 ng/ml, − 13.58, − 1.06, p = 0.023) were found in the CPAP-treated group compared with the control group, along with improvements in clinical parameters. Changes in AFABP were independently associated with both systolic blood pressure (β = 0.289, p = 0.028) and diastolic blood pressure (β = 0.217, p = 0.030). Conclusion: CPAP therapy used regularly over 4 weeks for severe OSA lowered circulating AFABP level, suggesting a potential beneficial effect of OSA treatment on alleviating metabolic risks. Trial registration: The research protocol was registered at the National Institutes of Health clinical trials registry (NCT01173432).-
dc.languageeng-
dc.publisherSpringer Verlag. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/11325-
dc.relation.ispartofSleep and Breathing-
dc.subjectAdipocyte fatty acid–binding protein-
dc.subjectObstructive sleep apnea-
dc.subjectContinuous positive airway pressure-
dc.subjectBiomarkers-
dc.titleCirculating adipocyte fatty acid–binding protein is reduced by continuous positive airway pressure treatment for obstructive sleep apnea—a randomized controlled study-
dc.typeArticle-
dc.identifier.emailLui, MMS: drmslui@hku.hk-
dc.identifier.emailMak, JCW: judithmak@hku.hk-
dc.identifier.emailLam, DCL: dcllam@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.authorityMak, JCW=rp00352-
dc.identifier.authorityLam, DCL=rp01345-
dc.identifier.authorityIp, MSM=rp00347-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s11325-019-01893-5-
dc.identifier.pmid31372823-
dc.identifier.scopuseid_2-s2.0-85086222448-
dc.identifier.hkuros314291-
dc.identifier.volume24-
dc.identifier.issue3-
dc.identifier.spage817-
dc.identifier.epage824-
dc.identifier.isiWOS:000559837000004-
dc.publisher.placeGermany-
dc.identifier.issnl1520-9512-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats